- Price
- $4.98
- Day
- 0.00%
- Mkt Cap
- $90.11M
- 52W Range
- $4.19 – $16.94
- Volume
- 212.8K
- Beta
- 1.90
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Owlet remains a buy despite flat stock performance, supported by strong Q2 results and ongoing business evolution. Q2 revenue hit a record $33.9M (up 29.9% YoY), with gross margin rebounding to 54% and subscription growth driving margin expansion. Management maintained 2026 guidance, forecasting $120M revenue (13.5% growth) and $8M EBITDA, with international and subscription segments as key growth drivers.
Read full article
Owlet, Inc. offers the only FDA-approved wearable infant monitor, leveraging patents and data to build a subscription-based telehealth platform. OWLT's pivot to a recurring subscription model targets 1 million users, aiming for higher margins and revenue stability amid ongoing cash burn. Gross margin guidance was raised to 53-55%, with 2026 revenue reaffirmed at $118-$122 million, but near-term profitability remains elusive.
Read full article